Evidence map›Paper›PMID 27367722›Full record

ArticleNutrients2016

Supplementation of Reduced Gluten Barley Diet with Oral Prolyl Endopeptidase Effectively Abrogates Enteropathy-Associated Changes in Gluten-Sensitive Macaques.

Karol Sestak, Hazel Thwin, Jason Dufour, David X Liu, Xavier Alvarez, David Laine, Adam Clarke, Anthony Doyle, Pyone P Aye, James Blanchard and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Association of Primate Veterinarians' Guidelines for the Judicious Use of Antimicrobials.Journal of the American Association for Laboratory Animal Science : JAALAS · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Karol SestakDivision of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, USA. ksestak@tulane.edu.
Hazel ThwinDivision of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, USA. hthwin@tulane.edu.
Jason DufourDivision of Veterinary Medicine, Tulane National Primate Research Center, Covington, LA 70433, USA. jdufour@tulane.edu.
David X LiuDivision of Comparative Pathology, Tulane National Primate Research Center, Covington, LA 70433, USA. dliu1@tulane.edu.
Xavier AlvarezDivision of Comparative Pathology, Tulane National Primate Research Center, Covington, LA 70433, USA. Xavier@tulane.edu.
David LaineTEVA Biologics, Discovery & Development, Sydney, Macquarie Park 2113, NSW, Australia. David.Laine@tevapharm.com.
Adam ClarkeTEVA Biologics, Discovery & Development, Sydney, Macquarie Park 2113, NSW, Australia. Adam.Clarke@tevapharm.com.
Anthony DoyleTEVA Biologics, Discovery & Development, Sydney, Macquarie Park 2113, NSW, Australia. Anthony.Doyle@tevapharm.com.
Pyone P AyeDivision of Veterinary Medicine, Tulane National Primate Research Center, Covington, LA 70433, USA. paye@tulane.edu.
James BlanchardDivision of Veterinary Medicine, Tulane National Primate Research Center, Covington, LA 70433, USA. jblanch1@tulane.edu.
Charles P MoehsArcadia Biosciences Inc., Seattle, WA 98119, USA. max.moehs@arcadiabio.com.
Tulane University · USTeva Pharmaceuticals (Australia) · AUArcadia Biosciences (United States) · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Reduced gluten cereal grainsR42DK097976 · NIDDK · ARCADIA BIOSCIENCES, INC. · PI VAN BOXTEL, JOS H · 2013 to 2016
$2.0M
Leica TCS SP8 Confocal Microscope SystemS10OD019964 · OD · TULANE UNIVERSITY OF LOUISIANA · PI LACKNER, ANDREW A · 2015 to 2015
$478k
NIDDK NIH HHS R42 DK097976NIH HHS P51 OD011104NIH HHS S10 OD019964
6 · The paper itself

Abstract

Celiac disease (CD) is an autoimmune disorder that affects approximately three million people in the United States. Furthermore, non-celiac gluten sensitivity (NCGS) affects an estimated additional 6% of the population, e.g., 20 million in the U.S. The only effective treatment of CD and NCGS requires complete removal of gluten sources from the diet. While required adherence to a gluten-free diet (GFD) is extremely difficult to accomplish, efforts to develop additional supportive treatments are needed. To facilitate these efforts, we developed a gluten-sensitive (GS) rhesus macaque model to study the effects of novel therapies. Recently reported results from phase one of this project suggest that partial improvement-but not remission-of gluten-induced disease can be accomplished by 100-fold reduction of dietary gluten, i.e., 200 ppm-by replacement of conventional dietary sources of gluten with a mutant, reduced gluten (RG) barley (lys3a)-derived source. The main focus of this (phase two) study was to determine if the inflammatory effects of the residual gluten in lys3a mutant barley grain could be further reduced by oral supplementation with a prolylendopeptidase (PE). Results reveal that PE supplementation of RG barley diet induces more complete immunological, histopathological and clinical remission than RG barley diet alone. The combined effects of RG barley diet and PE supplementation resulted in a further decrease of inflammatory mediators IFN-γ and TNF secretion by peripheral lymphocytes, as well as decreased plasma anti-gliadin and anti-intestinal tissue transglutaminase (TG2) antibodies, diminished active caspase production in small intestinal mucosa, and eliminated clinical diarrhea-all comparable with a gluten-free diet induced remission. In summary, the beneficial results of a combined RG barley and PE administration in GS macaques may warrant the investigation of similar synergistic approaches.

Indexed as

Diet, Gluten-FreeAnimalsCeliac DiseaseDisease Models, AnimalGliadinGlutensGTP-Binding ProteinsHordeumImmunoglobulin GInterleukin-15Intestine, SmallMacaca mulattaProlyl OligopeptidasesProtein Glutamine gamma Glutamyltransferase 2Serine EndopeptidasesTransglutaminasesGliadinGlutensGTP-Binding ProteinsImmunoglobulin GInterleukin-15Prolyl OligopeptidasesProtein Glutamine gamma Glutamyltransferase 2Serine EndopeptidasesTransglutaminasesceliacglutenglutenasegluten-freegluten-sensitive enteropathyIL-15oral supplementproteaserhesus macaque

Identifiers

PMID27367722
PMCPMC4963877
OpenAlexW2466173038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.